Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,611.70 | 38.30 | 0.45% |
| CAC 40 | 7,900.65 | 41.77 | -0.53% |
| DAX 40 | 23,985.89 | 50.22 | -0.21% |
| Dow JONES (US) | 42,677.24 | 114.83 | -0.27% |
| FTSE 100 | 8,783.65 | 2.53 | 0.03% |
| HKSE | 23,827.78 | 146.30 | 0.62% |
| NASDAQ | 19,142.71 | 72.75 | -0.38% |
| Nikkei 225 | 37,298.98 | 230.51 | -0.61% |
| NZX 50 Index | 12,703.10 | 58.87 | 0.47% |
| S&P 500 | 5,940.46 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,386.80 | 43.50 | 0.52% |
| SSE Composite Index | 3,387.57 | 7.10 | 0.21% |